Structure Therapeutics Files for IPO on NASDAQ to Raise $119M
Structure Therapeutics Inc. (Nasdaq: GPCR), a Sino-US firm formerly known as ShouTi Inc., has filed...
Diabetes
Guangzhou’s Overseas Pharma Wins China Clinical Trial Approval for OPL-038
Guangzhou-based Overseas Pharmaceuticals, Ltd has secured clinical trial approval in China for its sustained and...
Sanofi’s iGlarLixi Approved in China for Type 2 Diabetes Management
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that the National Medical Products Administration (NMPA)...
Innovent Biologics Doses First Patient in Phase III Study for Mazdutide
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient has been dosed...
HighTide Therapeutics Completes $107 Million Series C and C+ Financing Rounds
China-based HighTide Therapeutics Inc. has announced the completion of Series C and C+ financing rounds,...
Sihuan’s Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline
China – based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion...
BrightGene Receives NMPA Approval for BGM0504 Clinical Trial
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has announced that it has received clinical...
PingAn Good Doctor Partners to Establish Lifestyle Medicine
China-based PingAn Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor,...
Tonghua Dongbao Licenses Biosimilar Victoza to Kexing for Emerging Markets
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced a licensing agreement with compatriot firm Kexing Pharmaceutical...
Jiangsu Hengrui Gets NMPA Approval for HR20031 Clinical Study in Type 2 Diabetes
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving approval from the National Medical Products...
China Updates Hypertension Guidelines, Lowers Diagnostic Threshold
The National Center for Cardiovascular Diseases, the Chinese Medical Doctor Association (CMDA), and other organizations...
Novo Nordisk Reports 16% YOY Growth in Q3, Raises Full-Year Guidance
Denmark-based biopharma Novo Nordisk A/S (NYSE: NVO) has released its Q3 2022 earnings report. The...
Eccogene Gains FDA Approval for Phase I Study of ECC5004
Shanghai-based Eccogene has announced receiving approval from the US FDA to initiate a Phase I...
Shanghai SMPA Suspends HEC’s Linagliptin Procurement Over Patent Infringement
The Shanghai Sunshine Medical Procurement All-in-One (SMPA) platform has revealed that it has suspended the...
Hua Medicine Launches Dorzagliatin, a First-in-Class Diabetes Drug, in China
China-based Hua Medicine has announced the commercial launch of its Category 1 drug, dorzagliatin, with...
United Labs Gains NMPA Approval for Ozempic Biosimilar IND
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products...
YiChang HEC ChangJiang Pharma’s Insulin Aspart Gains NMPA Approval
China-based firm YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that its in-house...
Sciwind Biosciences Initiates US Phase I Study for GLP-1 Agonist XW014
China-based Sciwind Biosciences Co., Ltd has announced the initiation and first patient dosing of a...
Hua Medicine’s Dorzagliatin Approved in China for Type 2 Diabetes
China-based Hua Medicine (HKG: 2552) has announced that its Category 1 drug dorzagliatin has been...
Tasly Pharmaceuticals Gains NMPA Approval for B1344 Diabetes Study
China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the National...